Aim Immunotech Inc (AIM)
$2.43 0.01 (0.41%)
20:00 EDT AIM Stock Quote Delayed 30 Minutes
Previous Close $2.43
Market Cap -
PE Ratio -
Volume (Avg. Vol.) 1.81M
Day's Range 2.36 - 2.44
52-Week Range 0.38 - 7.41
Dividend & Yield N/A (N/A)
AIM Stock Predictions, Articles, and Aim Immunotech Inc News
- From InvestorPlace
- From the Web
AIM stock has entered Wall Street’s consciousness due to the underlying biotech firm’s potential coronavirus treatment. However, will this be enough to keep shares moving higher?
One big breakthrough moment in coronavirus research could bring wealth to AIM ImmunoTech. It could also bring big gains to AIM stock.
Though AIM stock is relevant on paper, with competition raging in the race for a coronavirus treatment, along with AIM ImmunoTech's checkered past, this is a very speculative gamble.
AIM ImmunoTech reported its 2019 results on March 31. Despite the coronavirus push, AIM stock headed lower on the news.
One of the few sectors that have enjoyed upside is the pharmaceutical industry. In particular, AIM stock has jumped on a possible Covid-19 treatment. Nevertheless, you want to look carefully at the label before jumping aboard.
AIM stock was a big winner on hopes it could join the response to the coronavirus. But its history suggests those hopes are too optimistic.
GT Biopharma (GTBP) news for Tuesday about it working on a possible treatment for the coronavirus from China has GTBP stock heading higher.
AIM ImmunoTech (AIM) news for Monday concerning a possible treatment for the coronavirus from China has AIM stock rocketing higher.
From Market News Video
Investors in Generac Holdings Inc (GNRC) saw new options become available this week, for the February 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
From Analyst Ratings
In a report released yesterday, Christopher Glynn from Oppenheimer assigned a Buy rating to Generac Holdings (GNRC – Research Report), with a price target of $120.00. The company’s shares closed last Monday at $117.02, close to its 52-week high of $123.19. According to TipRanks.com, Glynn is a 5-star analyst with an average return of 6.1%
From Analyst Ratings
There’s a lot to be optimistic about in the Conglomerates sector as 3 analysts just weighed in on Generac Holdings (GNRC – Research Report), WR Grace (GRA – Research Report) and Cabot (CBT – Research Report) with bullish sentiments. Generac Holdings (GNRC) Robert W. Baird analyst Michael Halloran maintained a Buy rating on Generac Holdings
Navellier RatingsPowered by Portfolio Grader